Alteon completes SAPPHIRE enrollment

ALT completed enrollment of 450 patients in its double-blind, placebo-controlled dose-ranging Phase IIb SAPPHIRE trial of ALT-711 to treat systolic hypertension. ALT's compound, which inhibits advance...